RegenTec, based in Nottingham, UK, (website) have intellectual property and expertise in degradable scaffold design and fabrication methods. This includes i) optimisation of the surface signalling of synthetic materials, ii) micropatterning of surfaces to control spatial development of tissues, iii) co-culture models to provide cell-cell signalling, iv) injectable solidifying delivery systems, and v) introduction of porosity and proteins to facilitate efficient nutrient transfer, control tissue architecture, and to mimic endogenous growth factor release. RegenTec is a spin-out company from the Tissue Engineering Group at the School of Pharmacy, and occupies over 1,100 sq ft of office and laboratory space at BioCity Nottingham. Our laboratories are fully equipped for tissue culture experiments, and wholly-owned assets include a Class II cabinet, two CO2 incubators, microgravity bioreactor, gel electrophoresis, electrophysiology apparatus, stereomicroscope and an inverted fluorescence microscope. In addition, RegenTec have access to the state-of-the-art research facilities within the Institute of Pharmaceutical Sciences.

RegenTec's contribution to the Osteocord project is the production of biodegradable, optimised scaffold materials optimised for CB-MSCs and in vitro biocompatibility testing.

RegenTec, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK

Dr Robin Quirk e-mail	Dr Cheryl Hunter e-mail

Click on the links to access the other Partners:

1. University of York, UK
2. University Hospital of Odense, Denmark
3. University of Southern Denmark
4. Fraunhofer Institute for Biomedical Engineering
5. University of Nottingham, UK
6. Institute of Transfusion Medicine and Immunology, Mannheim, Germany
7. Angel Biotechnology, Edinburgh, Scotland
8. EC Bio, Oeiras, Portugal
9. Regentec, Nottingham, UK